Metastatic Solid Tumor clinical trials

Explore recruiting metastatic solid tumor clinical trials.

Recruiting metastatic solid tumor studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Solid Tumor trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

Spain, France, Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

AcSé pemigatinib: Phase II trial evaluating the efficacy of pemigatinib in patients with recurrent and/or metastatic solid tumor harboring a FGFR alteration

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants with Advanced Solid Tumors

France, Spain, Netherlands, Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

France, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

PHASE 1/2, OPEN-LABEL, MULTICENTER, FIRST IN-HUMAN STUDY OF DS-3939a IN SUBJECTS WITH ADVANCED SOLID TUMORS

France, Spain, Belgium

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Metastatic Solid Tumor trials by city

Metastatic Solid Tumor in Toronto Metastatic Solid Tumor in Vancouver Metastatic Solid Tumor in Montreal Metastatic Solid Tumor in Calgary Metastatic Solid Tumor in Edmonton Metastatic Solid Tumor in Ottawa Metastatic Solid Tumor in Winnipeg Metastatic Solid Tumor in Quebec City Metastatic Solid Tumor in Hamilton Metastatic Solid Tumor in Kitchener Metastatic Solid Tumor in London Metastatic Solid Tumor in Halifax Metastatic Solid Tumor in New York Metastatic Solid Tumor in Los Angeles Metastatic Solid Tumor in Chicago Metastatic Solid Tumor in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease